Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 11,294,920
  • Shares Outstanding, K 155,150
  • Annual Sales, $ 18,760 K
  • Annual Income, $ -684,630 K
  • EBIT $ -612 M
  • EBITDA $ -631 M
  • 60-Month Beta 0.93
  • Price/Sales 601.82
  • Price/Cash Flow N/A
  • Price/Book 6.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.18
  • Most Recent Earnings $-1.27 on 11/10/25
  • Next Earnings Date 05/14/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 0.00% (-11.92%)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 121.12% on 07/14/25
  • IV Low 0.00% on 03/02/26
  • Expected Move (DTE 17) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 891
  • Volume Avg (30-Day) 1,985
  • Put/Call OI Ratio 8.29
  • Today's Open Interest 74,503
  • Open Int (30-Day) 53,520
  • Expected Range 14.43 to 14.43

Most Recent Stories

More News
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform

RNA : 14.52 (-2.62%)
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 14.52 (-2.62%)
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

SAN DIEGO , Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 14.52 (-2.62%)
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing

RNA : 14.52 (-2.62%)
Avidity Biosciences Announces Expected Record Date for Spin-Off

SAN DIEGO , Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 14.52 (-2.62%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO

NEW YORK , Jan. 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

RNA : 14.52 (-2.62%)
NWE : 69.17 (-1.12%)
TWO : 9.91 (-2.94%)
TBHC : 1.0500 (-2.78%)
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.58 (+0.64%)
TCBX : 40.22 (+1.54%)
RNA : 14.52 (-2.62%)
FSUN : 35.88 (-3.34%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 12.58 (+0.64%)
TCBX : 40.22 (+1.54%)
RNA : 14.52 (-2.62%)
FSUN : 35.88 (-3.34%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

TCBX : 40.22 (+1.54%)
RNA : 14.52 (-2.62%)
FIZN : 75.0100 (+5.20%)
WTRG : 39.59 (-1.39%)
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 14.52 (-2.62%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar